BRISTOL, Tenn. The Food and Drug Administration has approved a new drug made by Graceway Pharmaceuticals for treating a skin condition resulting from sun damage, Graceway announced Friday.
Zyclara (imiquimod) is a skin cream for treating actinic keratoses, a sign of skin damage resulting from long-term exposure to ultraviolet rays from the sun. The sun’s rays can cause changes in the size, shape and organization of the top layer of skin cells and the cells just below them. AK is considered a pre-caner and can be confused with age spots, eczema or psoriasis.
Zyclara has the same active ingredient as Aldara, a drug also used to treat AK that Graceway has acquire, though there are differences between the two, such as Zyclara’s approval for daily use.